MyMD Pharmaceuticals, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) operates as a clinical-stage biopharmaceutical company focused on developing novel therapies that target the causes of age-related diseases, autoimmune disorders, and inflammatory conditions; its primary pipeline includes the MYMD-1 platform, an oral small-molecule TNF-alpha inhibitor designed to regulate immunometabolic pathways, control chronic inflammation, and treat indications such as sarcopenia, rheumatoid arthritis, Hashimoto's thyroiditis, and longevity extension, alongside the Supera-CBD platform, a synthetic cannabidiol derivative for chronic pain, addiction, and epilepsy. Founded in 2014 and headquartered in Baltimore, Maryland, with recent operations noted in Tampa, Florida, the company serves global markets through its investigational new drug applications cleared by the U.S. Food and Drug Administration. In mid-2024, MyMD rebranded to TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) to emphasize its TNF-alpha focus, following positive topline Phase 2 results for MYMD-1 in sarcopenia; it secured $14 million in private placements led by strategic investor PharmaCyte Biotech, Inc., including $7 million in Series G preferred stock and additional commitments from existing shareholders to advance mid-stage trials in sarcopenia and other autoimmune indications.
TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol “TNFA” Effective Before Market Open Today
MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer
MyMD Pharmaceuticals Secures Strategic Investments
PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
Why Is MyMD Pharmaceuticals (MYMD) Stock Up 35% Today?
MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
MyMD Pharmaceuticals Releases Positive Clinical Trial Results For Sarcopenia Treatment Drug
MyMD Tackles Rheumatoid Arthritis with Launch of Phase 2 Trial in Early 2024
MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis
MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023
FDA Accepts MyMD Pharmaceuticals' Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1® in Rheumatoid Arthritis (RA)
MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial Results
MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty
ADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022
What to Know About Buying Penny Stocks on July 11th
MyMD Pharmaceuticals to Participate in Two Investor Conferences During December 2021
Week 44 MDA Breakout Stocks - November 2021: Short-Term Picks To Give You An Edge
MyMD Pharmaceuticals to Discuss its Novel Therapies for Aging and Related Diseases at the Dawson James Securities 6th Annual Small Cap Growth Conference on October 21
MyMD Pharmaceuticals Announces New Data Demonstrating 8,000 Times Higher Potency of Novel Synthetic Supera-CBD over Plant-Derived CBD